The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Eleonora, Hamadani, Mehdi, Zinzani, Pier Luigi, Caimi, Paolo, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335500/
https://www.ncbi.nlm.nih.gov/pubmed/35580172
http://dx.doi.org/10.1182/blood.2021014663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335500/
https://www.ncbi.nlm.nih.gov/pubmed/35580172
http://dx.doi.org/10.1182/blood.2021014663

Ejemplares similares